Abstract
Objective of the Paper: Demonstration of a clinical case of successful use of golimumab in a child with juvenile polyarthritis. Key points. Juvenile polyarthritis is one of the most disabling clinical variants of juvenile idiopathic arthritis (JIA). In recent years, the range of medicines used in the therapy of JIA has significantly expanded. With the ineffectiveness of methotrexate, the appointment of genetically engineered biological drugs (GIBP) is shown, among which tumor necrosis factor α (TNF-α) inhibitors are most often used, one of which is golimumab. Conclusion. To date, for the treatment of juvenile polyarthritis, there is golimumab in the arsenal of medicines, which is human monoclonal antibodies to TNF-α, which allows to achieve an inactive phase of the disease with the ineffectiveness of the use of other GIBP. Keywords: juvenile polyarthritis, golimumab, children
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
